54 reports

The drug candidate is a recombinant galectin-## protein.

  • Protein Therapy
  • Therapy
  • World
  • Product Initiative
  • Strykagen Corp.
  • Gene Therapy for Hemophilia A
  • ET-3I - DRUG PROFILE

No specific treatment was given for the anti-OBI-## antibodies.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States

Of these proteins, albumin accounts for ##%, globulins for ##%, coagulation for ##% and other proteins for the remaining ##% share.

  • Blood Supply
  • Protein Therapy
  • World
  • Forecast
  • Grifols, S.A.
  • RESOLVED BY THE EGM HAS BECOME EFFECTIVE.

THE DRUG CANDIDATE IS A PROTEIN AND CELLULAR BASED THERAPY BASED RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) BIOLOGICAL NANOPARTICLE.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

PLASMA PROTEIN THERAPIES ARE USED TO TREAT RARE AND CHRONIC DISEASES.

  • Blood Disease
  • Blood Supply
  • Healthcare
  • Hospital
  • Protein Therapy

The Company is developing OPRX-## to be the first ever oral protein treatment, as currently there are no other oral protein treatments available.

  • Protein Therapy
  • Brazil
  • United States
  • Company
  • Protalix BioTherapeutics, Inc.

HUMAN PROTEIN AND THE COMPANY WAS THE FIRST ONE TO MAKE VIRUS INACTIVE FACTOR VIII PRODUCT.

  • Protein Therapy
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

Grifols is one of the world top three producers of plasma-derived therapies.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • In Vitro Diagnostic Reagent
  • Protein Therapy

Additionally, we are screening patients in Australia for our Phase ## clinical trial of FPT##, our first-in-class CD## fusion protein.

  • Protein Therapy
  • United States
  • Company
  • Company Financials
  • Five Prime Therapeutics, Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass ##, or IgG## (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life).

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States

SMAD## PROTEIN ACTS AS TGF BETA RECEPTOR TYPE ## ANTAGONIST.

  • Medical Supply
  • Protein Therapy
  • Wound Care
  • United States
  • Product Initiative
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

The study is being conducted at the Cincinnati Children' s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs).

  • Clinical Trial
  • Pharmaceutical
  • Protein Therapy
  • World
  • Product Initiative

MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy.

  • Clinical Trial
  • Neurological Disorder
  • Protein Therapy
  • World
  • Neuren Pharmaceuticals Limited
  • ET-3 - DRUG PROFILE

No specific treatment was given for the anti-OBI-## antibodies.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • United States
  • Alnylam Pharmaceuticals, Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

One case of nonserious rash and one case of myalgia were reported to be treatment-related.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • Novo Nordisk Group
  • Pfizer Inc.
  • BAYER HEALTHCARE: YOY REVENUE AND GROWTH RATE OF KOGENATE 2013-2015 ($ BILLIONS)
  • In March 2016, the company received US FDA approval for its recombinant hemophilia A drug, Kovaltry

Other mutations reduce the amount of protein but do not eliminate the protein' s activity, leading to mild or moderate hemophilia.

  • Protein Therapy
  • Baxalta Incorporated
  • Bayer AG
  • Biogen Idec Inc.
  • Grifols, S.A.

Most of the adverse effects (AEs) were grade ## or ##.

  • Cancer
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy
  • Therapy

This results in the silencing of messenger RNA (mRNA) that codes for proteins and prevents the production of these disease-causing proteins.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • Biogen Idec Inc.

## ## ##. ## ## ##. ## GlaxoSmithKline Plc Samsung Bioepis Co Ltd South Korea ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## UCB SA ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## ## ##. ## - ##. ## ## ## ##. ## ## - Biogen Inc United States ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## Gilead Sciences Inc Corbus

  • Arthritis
  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • Protein Therapy

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Protein Therapy
  • Tuberculosis
  • Orphan Dermatological Diseases, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type

Arthritis Research and Therapy. ##(##).

  • Dermatological Condition
  • Pathology
  • Protein Therapy
  • Therapy
  • Deals & Alliance

Arthritis Research Therapy; ##(##): ##-## Bridges D, et al. (2001).

  • Protein Therapy
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Insys Therapeutics, Inc.

Hoffmann-La Roche Ltd ## Jan 2010 ## Jun 2012 ## Jun 2012 ## ## ## ## Inosine Monophosphate Dehydrogenase (Inosinic Acid Dehydrogenase or IMP Oxidoreductase or IMPDH or EC ##. ##. ##. ##) Inhibitor Inosine Monophosphate Dehydrogenase (Inosinic Acid Dehydrogenase or IMP Oxidoreductase or IMPDH or

  • Clinical Trial
  • Lung Transplant
  • Protein Therapy
  • Therapy
  • Transplantation

IT IS A MODIFIED VERSION OF THE NATURAL PROTEIN ALPHA ## MICROGLOBULIN (A##M).

  • Genitourinary System Disease
  • Pathology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Protein expression of CTGF, fibronectin, PDGF-BB, TIMP-## and MCP-## detected in the culture media.

  • Genitourinary System Disease
  • Pathology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

COMPARED TO THE CONTROL GROUP, CD##MAB TREATMENT SIGNIFICANTLY DECREASED GENES EXPRESSION RELATED TO OXIDATIVE STRESS (SOD-##, GPX-##, AND TXN), THE INFLAMMATORY RESPONSE (IL-##, IL-##, INF-G AND TGF-B), AS WELL AS REDUCED PROTEIN LEVELS OF BAX, CASPASE-##, MMP##, AND M

  • Cardiovascular Disease
  • Hospital
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Compared to the control group, CD##mAb treatment significantly decreased genes expression related to oxidative stress (sod-##, gpx-##, and txn), the inflammatory response (il-##, il-##, inf-g and tgf-b), as well as reduced protein levels of BAX, Caspase-##, MMP##, and M

  • Cardiovascular Disease
  • Medical Biotechnology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

The CD##/ CD##L interaction results in the production of various cytokines, including TNF-α, IL##, IL##, IL##, IFN-γ and TGF-β, and chemokines, including monocyte chemotactic protein-## (MCP-##) and macrophage inflammatory protein ##, depending on which ce

  • Gastrointestinal Drug
  • Pharmaceutical
  • Protein Therapy
  • World
  • Deals & Alliance